<DOC>
	<DOCNO>NCT02001688</DOCNO>
	<brief_summary>To evaluate different dos `` Kamada-API Inhalation '' level alpha 1-proteinase inhibitor analytes epithelial line fluid ( ELF ) serum assess safety treatment subject Alpha-1 Antitrypsin Deficiency .</brief_summary>
	<brief_title>Phase II , Safety ELF Study `` Kamada-API Inhalation ''</brief_title>
	<detailed_description />
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<criteria>Male female patient 18 65 year age ( inclusive ) . Able willing sign inform consent . Males , nonpregnant , nonlactating female whose screen pregnancy test negative use contraceptive method deem reliable investigator postmenopausal surgically sterilize . Diagnosis alpha1antitrypsin deficiency [ individual ZZ Z null classification ] . FEV1 ( forced expiratory volume one second ) â‰¥ 50 % predict post bronchodilator No respiratory exacerbation within 6 week baseline . Subjects rescreened exacerbation exist time enrollment . No sign chronic and/or acute Hepatitis A , Hepatitis B , Hepatitis C , HIV infection Parvovirus B19 , NAT ( Parvovirus B19 , NAT result must &lt; 10^4 IU/mL ) . No significant abnormality serum hematology , serum chemistry , serum inflammatory / immunogenic marker urinalysis . No significant abnormality ECG . Not intravenous augmentation therapy least 8 week prior initial dose study drug/placebo willing forego intravenous augmentation therapy duration study . Clinically significant intercurrent illness ( except respiratory liver disease secondary AAT deficiency ) , include : cardiac , hepatic , renal , endocrine , neurological , hematological , neoplastic , immunological , skeletal ) opinion investigator , could interfere safety , compliance aspect study . Patients wellcontrolled , chronic disease could possibly include consultation treat physician sponsor . History life threaten allergy , anaphylactic reaction , systemic response human plasma derive product . History life threaten transfusion reaction . History lung transplant . Current previous ( 8 week baseline ) use AAT augmentation therapy route Current use oral parenteral glucocorticoid dose exceed 10mg prednisone daily equivalent generic ( substance dose ) . Any lung surgery within past two year . On thoracic surgery wait list . Active smoking last 12 month screen date . Pregnancy lactation . Woman childbearing potential take adequate contraception deem reliable investigator . Presence psychiatric/ mental disorder medical disorder might impair patient 's ability give inform consent comply requirement study protocol . Evidence alcohol abuse history alcohol abuse illegal and/or legally prescribe drug . IgA ( immunoglobulin A ) Deficiency . Inability undergo bronchoscopy . Allergy lidocaine medicine use bronchoscopy process Exacerbation COPD ( chronic obstructive pulmonary disease ) previous 6 week . Participation another clinical trial involve investigational medication interventional treatment within 30 day prior baseline visit . Participation observational clinical trial involve invasive procedure schedule occur AAT inhale study period . If participate observational clinical trial already complete diagnostic procedure ( e.g . liver biopsy ) , AEs experience must return baseline within 30 day prior baseline visit . Inability attend schedule clinic visit and/or comply study protocol . Any factor , opinion investigator , would prevent patient form complying requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>